Skip to main content
  1. Market Insights
  2. Health
  3. Pharmaceuticals
  4. Vaccines

COVID-19 Vaccines - North America

North America
  • The North American COVID-19 Vaccines market is forecasted to witness a significant revenue growth, projected to reach US$5.30bn by 2024.
  • This market is expected to exhibit a strong compound annual growth rate (CAGR 2024-2029) of -18.15%, leading to a substantial market volume of US$1.95bn by 2029.
  • In terms of global comparison, United States is poised to generate the highest revenue in the COVID-19 Vaccines market, with an estimated revenue of US$4.39bn in 2024.
  • In North America, the demand for COVID-19 vaccines has skyrocketed, with citizens eagerly lining up for their doses.

Definition:
This market covers vaccines against COVID-19. Included are different types of vaccines (mRNA-based, viral vector vaccines).

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Pfizer, Moderna, Biontech, Johnson & Johnson, AstraZeneca

In-Scope

  • COVID-19 vaccines
  • mRNA-based vaccines
  • Viral vector vaccines

Out-Of-Scope

  • Vaccines against other diseases
  • Antivirals
Pharmaceuticals: market data & analysis - Cover

Market Insights report

Pharmaceuticals: market data & analysis

Study Details

    Revenue

    Notes: Data shown is using current exchange rates and reflects market impacts of the Russia-Ukraine war.

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Notes: The chart “Comparable Estimates” shows the forecasted development of the selected market from different sources. Please see the additional information for methodology and publication date.

    Most recent update: Mar 2024

    Analyst Opinion

    The COVID-19 pandemic has had a significant impact on the global economy, including the pharmaceutical industry. The race to develop a vaccine for COVID-19 has been intense, and North America has been at the forefront of this effort.

    Customer preferences:
    The demand for COVID-19 vaccines in North America has been high due to the severity of the pandemic in the region. Customers are looking for vaccines that are safe, effective, and easily accessible. There is also a preference for vaccines that require only one dose, as this simplifies the vaccination process.

    Trends in the market:
    The COVID-19 vaccine market in North America has been dominated by Pfizer-BioNTech and Moderna. These two companies were the first to develop and receive emergency use authorization for their vaccines in the region. However, other companies such as Johnson & Johnson and AstraZeneca have also entered the market. The availability of multiple vaccines has increased the supply of vaccines in the region, which has helped to address the high demand.

    Local special circumstances:
    The United States has been the largest market for COVID-19 vaccines in North America. The country has a large population and has been one of the worst affected by the pandemic. The government has played a significant role in the distribution of vaccines, with the Biden administration setting a goal of vaccinating 70% of the adult population by July 4th, 2021. Canada has also been actively vaccinating its population, with a goal of vaccinating all eligible individuals by September 2021.

    Underlying macroeconomic factors:
    The COVID-19 pandemic has had a significant impact on the global economy, including the pharmaceutical industry. Governments around the world have invested heavily in the development and distribution of vaccines, which has created opportunities for pharmaceutical companies. In North America, the government has played a significant role in the distribution of vaccines, which has helped to address the high demand. The availability of vaccines has also had a positive impact on the economy, as it has allowed for the reopening of businesses and the resumption of economic activity.

    Global Comparison

    Most recent update: Jun 2024

    Source: Statista Market Insights

    Methodology

    Data coverage:

    Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

    Modeling approach / Market size:

    Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

    Forecasts:

    In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

    Additional notes:

    Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

    Health

    Access more Market Insights on Health topics with our featured report

    Pharmaceuticals: market data & analysis - BackgroundPharmaceuticals: market data & analysis - Cover

    Key Market Indicators

    Notes: Based on data from IMF, World Bank, UN and Eurostat

    Most recent update: Sep 2024

    Source: Statista Market Insights

    Explore more high-quality data on related topic

    Coronavirus (COVID-19): vaccines and vaccination campaign

    As of March 2023, more than 13 billion COVID-19 vaccine doses had been administered worldwide. Wide-spread vaccine availability, increasing herd immunity, and lower case numbers led to renewed hope and a feeling of normality in 2023. However, especially during the winter seasons and with the potential emergence of new variants of the virus (like Omicron in 2021-2022), tracking of coronavirus cases repeatedly becomes a focus for the public. Thus, there is a level of uncertainty about what developments the winter season 2023/2024 might bring.
    More data on the topic

    Contact

    Get in touch with us. We are happy to help.